MAY 14, 2020 5:00 PM EDT

Molecular Profiling for Treatment Guidance of Hematologic Malignancies by Next Generation Sequencing



Next-generation sequencing (NGS) has become the most effective tool in the practice of clinical oncology. The technology allows for rapid detection of variants in DNA/RNA simultaneously in a single run within a few days. The results provide valuable information on diagnostic, prognostic and therapeutic targets, which help physicians determine the treatment strategy for cancer patients. This presentation includes two parts. Part 1 will cover NCCN/CAP/ASH guidelines and treatment options for hematologic malignancies. Part 2 will share the experience with the Oncomine Myeloid Research Assay including technical validation and summary of the clinical data from over 1300 patients. Overall, the abnormality rate was 56%. Among these patients, 3% were MPN, 34% were AML, 10% were MDS, and 53% were other myeloid disorders. The most common variants detected include TET2, ASXL1, DNMT3A, RUNX1, TP53, FLT3, IDH1, IDH2, WT1, JAK2, CALR, and CEBPA. The fusions include BCR/ABL1, CBFB-MYH11, KMT2A fusions, RUNX1 fusions, and PML-RARA. These variants are clinically actionable with therapeutic drugs or have prognostic implications.  In summary, this presentation demonstrates that the NGS test is a robust and powerful tool for detecting genetic alterations associated with various types of cancers. This advanced tool will help maximize the benefit of precision medicine in the clinical oncology practice for cancer patients.


Learning Objectives:

1. Explain the overview of the guidelines and treatment options for hematologic neoplasms

2. Describe the clinical utility of targeted next generation sequencing tests in the context of myeloid neoplasms

You May Also Like
Loading Comments...